Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30744235 | 1.00 | PPARG (0.43) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL16288980 | 1.00 | PPARG (0.43) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL15083099 | 1.00 | PPARG (0.43) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL31072747 | 0.93 | PPARG (0.42) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL29855013 | 0.93 | PPARG (0.42) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL25179041 | 0.93 | PPARG (0.42) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL22454757 | 0.93 | PPARG (0.42) | PPARGPPARAALDH1A1LMNAPOLB | |
| SCHEMBL25179288 | 0.92 | PPARG (0.41) | PPARGPPARAALDH1A1LMNAFABP5 | |
| SCHEMBL25185711 | 0.92 | PPARG (0.41) | PPARGPPARAALDH1A1LMNAFABP5 | |
| SCHEMBL29855192 | 0.92 | PPARG (0.41) | PPARGPPARAALDH1A1LMNAFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-20250186542-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-12 | — | — | US | disclosed |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20240366711-A1 | PREPARATION CONTAINING CYCLIC PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-4299069-A1 | PREPARATION CONTAINING CYCLIC PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-03 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279928-A | Process for the preparation of cyclic compounds comprising N-substituted amino acid residues | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117241817-A | Formulations comprising cyclic peptide compounds and methods of making the same | 中外制药株式会社 | 2023-12-15 | — | — | CN | disclosed |
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-4086272-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-11-09 | — | — | EP | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | PPARG 3973/4885PPARA 3215/4885ALDH1A1 4857/4885 |
| US-20240366711-A1 | PREPARATION CONTAINING CYCLIC PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME | VIP, NGLY1, NPPA | PPARG 3393/4885PPARA 2033/4885ALDH1A1 4841/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | PPARG 2549/4885PPARA 2736/4885ALDH1A1 4331/4885 |
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | PPARG 4325/4885PPARA 3049/4885ALDH1A1 4672/4885 |
| US-20250186542-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | PCTP, CETP, PLTP | PPARG 665/4885PPARA 471/4885ALDH1A1 4712/4885 |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | NGLY1, NPPA, VIP | PPARG 4325/4885PPARA 3049/4885ALDH1A1 4672/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | PPARG 4325/4885PPARA 3049/4885ALDH1A1 4672/4885 |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | PCTP, CETP, PLTP | PPARG 874/4885PPARA 216/4885ALDH1A1 4623/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | PPARG 3973/4885PPARA 3215/4885ALDH1A1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.